WO2006108667A2 - Method of treatment using gh antagonist and somatostatin agonist - Google Patents
Method of treatment using gh antagonist and somatostatin agonist Download PDFInfo
- Publication number
- WO2006108667A2 WO2006108667A2 PCT/EP2006/003438 EP2006003438W WO2006108667A2 WO 2006108667 A2 WO2006108667 A2 WO 2006108667A2 EP 2006003438 W EP2006003438 W EP 2006003438W WO 2006108667 A2 WO2006108667 A2 WO 2006108667A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pegvisomant
- human
- once
- somatostatin
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
Definitions
- the present invention relates to a method and compositions useful for attenuating the effects of elevated levels of growth hormone (GH) in the blood. More particularly, the present invention relates to the reduction of GH levels and/or insulin-like growth factor-1 (IGF-1) levels in the blood by the administration of a combination of a GH antagonist with a somatostatin or somatostatin agonist.
- GH growth hormone
- IGF-1 insulin-like growth factor-1
- Conditions related to GH excess are well known to medical practitioners.
- One of the best known examples of such conditions, acromegaly is characterized by excessive levels of GH in the blood, often resulting from an adenoma of the anterior pituitary.
- Acromegaly is associated with significant risk of morbidity (soft-tissue swelling, arthralgia, headache, perspiration, fatigue, CV disorders), insulin resistance and diabetes, vision problems resulting from optic nerve compression by the adenoma, and premature mortality.
- Most of the biological impacts and symptoms related to GH excess are mediated through IGF-1 , which is secreted by the liver as well as many other target organs as a result of GH receptor activation.
- GH suppressive drugs Traditional treatment options for acromegaly include surgical removal of the offending tumor with or without follow-on, and normally chronic, medical treatment with GH suppressive drugs.
- somatostatin analogs such as LANREOTIDE (Ipsen, Paris, France) and OCTREOTIDE (Novartis, Basle, Switzerland) and dopamine agonists such as bromocriptine, cabergoline, and pergolide.
- dopamine agonists while generally effective at providing symptomatic relief, rarely normalize GH levels.
- LANREOTIDE and OCTREOTIDE are able to reduce GH and IGF-1 levels in approximately 90% of acromegalic patients.
- PEGVISOMANT SOMAVERT, Pfizer, Inc., New York, USA
- PEGVISOMANT comprises a recombinantly produced, 191 amino acid analog of the GH protein to which polyethyleneglycol moieties have been attached (i.e., the protein has been subjected to "pegylation").
- pegylation a method of producing recombinant proteins, and in particular, growth hormone antagonists, are well known to persons skilled in the art of pharmacy.
- GH antagonists like PEGVISOMANT are believed to competitively bind to, but not activate, the GH receptor, thereby substantially attenuating most of the effects of high levels of circulating endogenous GH (i.e., normalize IGF-I levels) in most (e.g., 75% - 95%) acromegalics.
- Pegylation of the GH antagonist protein is intended to improve in vivo half-life and reduce immunogenicity. (Kopchick et al., Endocrine Rev, (2002), 23(5) pp.623-646.)
- GH antagonist demonstrates that, while this class of therapeutic agent may be generally effective at alleviating most negative effects of high circulating endogenous GH levels, relatively high in vivo concentrations of a GH antagonist are required in order to compete effectively for the GH receptor, hence a high dose must be administered (10 to 40 mg per day or higher in the case of Pegvisomant). Further, while pegylation of the GH antagonist protein offers improved in vivo half-life relative to the non-pegylated form, currently practice with PEGVISOMANT demonstrates that this type of therapeutic agent often needs to be administered on a daily basis in order to assure efficacy.
- the invention relates to a method for attenuating the effects of GH in a human or non-human subject in whom such attenuation is desired, said method comprising administering to said subject both a GH antagonist and a somatostatin or a somatostatin agonist.
- said subject is a mammal.
- said mammal is a human being, more preferably a human being whose blood plasma level of GH is higher than desired, more preferably still a human being who is suffering from acromegaly or who is at risk of developing acromegaly or symptoms thereof.
- said subject is a human who suffers from acromegaly and said GH antagonist comprises PEGVISOMANT, wherein said PEGVISOMANT is administered with a frequency of between about once per day and about once every month, inclusive, preferably between about once every 3 days (i.e., about every 2, 3, or 4 days) and about once every 14 days, inclusive, more preferably about once per week, (i.e., about once every 5, 6, 7, 8, or 9 days), most preferably about once every 7 days.
- PEGVISOMANT is administered with a frequency of between about once per day and about once every month, inclusive, preferably between about once every 3 days (i.e., about every 2, 3, or 4 days) and about once every 14 days, inclusive, more preferably about once per week, (i.e., about once every 5, 6, 7, 8, or 9 days), most preferably about once every 7 days.
- said subject is a human who suffers from acromegaly and said somatostatin agonist comprises OCTREOTIDE or LANREOTIDE, wherein said OCTREOTIDE or said LANREOTIDE is administered with a frequency of between about five times per day and about once every 6 months, inclusive, preferably between about three times per day and about once every 3 months, inclusive, more preferably between about once per day and about once per month, inclusive, more preferably about once per month. More preferably when said somatostatin agonist is OCTREOTIDE it is provided as OCTREOTIDE LAR, and when said somatostatin agonist is LANREOTIDE it is provided as LANREOTIDE AUTOGEL.
- said human subject suffers from acromegaly, said GH antagonist comprises PEGVISOMANT, and said somatostatin agonist comprises OCTREOTIDE, wherein said PEGVISOMANT is administered about once per week and said OCTREOTIDE is administered about once per month.
- said human subject suffers from acromegaly, said GH antagonist comprises PEGVISOMANT, and said somatostatin agonist comprises LANREOTIDE, wherein said PEGVISOMANT is administered about once per week and said LANREOTIDE is administered about once per month.
- the invention in a second aspect, relates to a method for reducing the dose of GH antagonist needed to attenuate the effects of GH in a human or non-human subject in whom such attenuation is desired, said method comprising administering to said subject both a GH antagonist and a somatostatin or a somatostatin agonist.
- said subject is a mammal.
- said mammal is a human being, more preferably a human being whose blood plasma level of GH is higher than desired, more preferably still a human being who is suffering from acromegaly or who is at risk of developing acromegaly or symptoms thereof.
- said subject is a human who suffers from acromegaly and said GH antagonist comprises PEGVISOMANT, wherein said PEGVISOMANT is administered with a frequency of between about once per day and about once every month, inclusive, preferably between about once every 3 days (i.e., about every 2, 3, or 4 days) and about once every 14 days, inclusive, more preferably about once per week, (i.e., about once every 5, 6, 7, 8, or 9 days), most preferably about once every 7 days.
- PEGVISOMANT is administered with a frequency of between about once per day and about once every month, inclusive, preferably between about once every 3 days (i.e., about every 2, 3, or 4 days) and about once every 14 days, inclusive, more preferably about once per week, (i.e., about once every 5, 6, 7, 8, or 9 days), most preferably about once every 7 days.
- said subject is a human who suffers from acromegaly and said somatostatin agonist comprises OCTREOTIDE or LANREOTIDE, wherein said OCTREOTIDE or said LANREOTIDE is administered with a frequency of between about five times per day and about once every 6 months, inclusive, preferably between about three times per day and about once every 3 months, inclusive, more preferably between about once per day and about once per month, inclusive, more preferably about once per month. More preferably when said somatostatin agonist is OCTREOTIDE it is provided as OCTREOTIDE LAR, and when said somatostatin agonist is LANREOTIDE it is provided as LANREOTIDE AUTOGEL.
- said human subject suffers from acromegaly, said GH antagonist comprises PEGVISOMANT, and said somatostatin agonist comprises OCTREOTIDE, wherein said PEGVISOMANT is administered about once per week and said OCTREOTIDE is administered about once per month.
- said human subject suffers from acromegaly, said GH antagonist comprises PEGVISOMANT, and said somatostatin agonist comprises LANREOTIDE, wherein said PEGVISOMANT is administered about once per week and said LANREOTIDE is administered about once per month.
- the invention in a third aspect, relates to a method for reducing the frequency of administration of GH antagonist needed to attenuate the effects of GH in a human or non-human subject in whom such attenuation is desired, said method comprising administering to said subject both a GH antagonist and a somatostatin or a somatostatin agonist.
- said subject is a mammal.
- said mammal is a human being, more preferably a human being whose blood plasma level of GH is higher than desired, more preferably still a human being who is suffering from acromegaly or who is at risk of developing acromegaly or symptoms thereof.
- said subject is a human who suffers from acromegaly and said GH antagonist comprises PEGVISOMANT, wherein said PEGVISOMANT is administered with a frequency of between about once per day and about once every month, inclusive, preferably between about once every 3 days (i.e., about every 2, 3, or 4 days) and about once every 14 days, inclusive, more preferably about once per week, (i.e., about once every 5, 6, 7, 8, or 9 days), most preferably about once every 7 days.
- PEGVISOMANT is administered with a frequency of between about once per day and about once every month, inclusive, preferably between about once every 3 days (i.e., about every 2, 3, or 4 days) and about once every 14 days, inclusive, more preferably about once per week, (i.e., about once every 5, 6, 7, 8, or 9 days), most preferably about once every 7 days.
- said subject is a human who suffers from acromegaly and said somatostatin agonist comprises OCTREOTIDE or LANREOTIDE, wherein said OCTREOTIDE or said LANREOTIDE is administered with a frequency of between about five times per day and about once every 6 months, inclusive, preferably between about three times per day and about once every 3 months, inclusive, more preferably between about once per day and about once per month, inclusive, more preferably about once per month. More preferably when said somatostatin agonist is OCTREOTIDE it is provided as OCTREOTIDE LAR, and when said somatostatin agonist is LANREOTIDE it is provided as LANREOTIDE AUTOGEL.
- said human subject suffers from acromegaly, said GH antagonist comprises PEGVISOMANT, and said somatostatin agonist comprises OCTREOTIDE, wherein said PEGVISOMANT is administered about once per week and said OCTREOTIDE is administered about once per month.
- said human subject suffers from acromegaly, said GH antagonist comprises PEGVISOMANT, and said somatostatin agonist comprises LANREOTIDE, wherein said PEGVISOMANT is administered about once per week and said LANREOTIDE is administered about once per month.
- the invention in a fourth aspect, relates to a method for normalizing serum IGF-I concentration in a human or non-human subject in whom such normalization is desired, said method comprising administering to said subject both a GH antagonist and a somatostatin or a somatostatin agonist.
- said subject is a mammal.
- said mammal is a human being, more preferably a human being whose blood plasma level of GH is higher than desired, more preferably still a human being who is suffering from acromegaly or who is at risk of developing acromegaly or symptoms thereof.
- said subject is a human who suffers from acromegaly and said GH antagonist comprises PEGVISOMANT, wherein said PEGVISOMANT is administered with a frequency of between about once per day and about once every month, inclusive, preferably between about once every 3 days (i.e., about every 2, 3, or 4 days) and about once every 14 days, inclusive, more preferably about once per week, (i.e., about once every 5, 6, 7, 8, or 9 days), most preferably about once every 7 days.
- PEGVISOMANT is administered with a frequency of between about once per day and about once every month, inclusive, preferably between about once every 3 days (i.e., about every 2, 3, or 4 days) and about once every 14 days, inclusive, more preferably about once per week, (i.e., about once every 5, 6, 7, 8, or 9 days), most preferably about once every 7 days.
- said subject is a human who suffers from acromegaly and said somatostatin agonist comprises OCTREOTIDE or LANREOTIDE, wherein said OCTREOTIDE or said LANREOTIDE is administered with a frequency of between about five times per day and about once every 6 months, inclusive, preferably between about three times per day and about once every 3 months, inclusive, more preferably between about once per day and about once per month, inclusive, more preferably about once per month. More preferably when said somatostatin agonist is OCTREOTIDE it is provided as OCTREOTIDE LAR, and when said somatostatin agonist is LANREOTIDE it is provided as LANREOTIDE AUTOGEL.
- said human subject suffers from acromegaly, said GH antagonist comprises PEGVISOMANT, and said somatostatin agonist comprises OCTREOTIDE, wherein said PEGVISOMANT is administered about once per week and said OCTREOTIDE is administered about once per month.
- said human subject suffers from acromegaly, said GH antagonist comprises PEGVISOMANT, and said somatostatin agonist comprises LANREOTIDE, wherein said PEGVISOMANT is administered about once per week and said LANREOTIDE is administered about once per month.
- the invention relates to a method for reducing the dose of GH antagonist needed to normalize the serum IGF-I concentration in a human or non-human subject in whom such normalization is desired, said method comprising administering to said subject both a GH antagonist and a somatostatin or a somatostatin agonist.
- said subject is a mammal.
- said mammal is a human being, more preferably a human being whose blood plasma level of GH is higher than desired, more preferably still a human being who is suffering from acromegaly or who is at risk of developing acromegaly or symptoms thereof.
- said subject is a human who suffers from acromegaly and said GH antagonist comprises PEGVISOMANT, wherein said PEGVISOMANT is administered with a frequency of between about once per day and about once every month, inclusive, preferably between about once every 3 days (i.e., about every 2, 3, or 4 days) and about once every 14 days, inclusive, more preferably about once per week, (i.e., about once every 5, 6, 7, 8, or 9 days), most preferably about once every 7 days.
- PEGVISOMANT is administered with a frequency of between about once per day and about once every month, inclusive, preferably between about once every 3 days (i.e., about every 2, 3, or 4 days) and about once every 14 days, inclusive, more preferably about once per week, (i.e., about once every 5, 6, 7, 8, or 9 days), most preferably about once every 7 days.
- said subject is a human who suffers from acromegaly and said somatostatin agonist comprises OCTREOTIDE or LANREOTIDE, wherein said OCTREOTIDE or said LANREOTIDE is administered with a frequency of between about five times per day and about once every 6 months, inclusive, preferably between about three times per day and about once every 3 months, inclusive, more preferably between about once per day and about once per month, inclusive, more preferably about once per month. More preferably when said somatostatin agonist is OCTREOTIDE it is provided as OCTREOTIDE LAR, and when said somatostatin agonist is LANREOTIDE it is provided as LANREOTIDE AUTOGEL.
- said human subject suffers from acromegaly, said GH antagonist comprises PEGVISOMANT, and said somatostatin agonist comprises OCTREOTIDE, wherein said PEGVISOMANT is administered about once per week and said OCTREOTIDE is administered about once per month.
- said human subject suffers from acromegaly, said GH antagonist comprises PEGVISOMANT, and said somatostatin agonist comprises LANREOTI DE, wherein said PEGVISOMANT is administered about once per week and said LANREOTIDE is administered about once per month.
- the invention relates to a method for reducing the frequency of administration of GH antagonist needed to normalize the serum IGF-I concentration in a human or non-human subject in whom such normalization is desired, said method comprising administering to said subject both a GH antagonist and a somatostatin or a somatostatin agonist.
- said subject is a mammal.
- said mammal is a human being, more preferably a human being whose blood plasma level of GH is higher than desired, more preferably still a human being who is suffering from acromegaly or who is at risk of developing acromegaly or symptoms thereof.
- said subject is a human who suffers from acromegaly and said GH antagonist comprises PEGVISOMANT, wherein said PEGVISOMANT is administered with a frequency of between about once per day and about once every month, inclusive, preferably between about once every 3 days (i.e., about every 2, 3, or 4 days) and about once every 14 days, inclusive, more preferably about once per week, (i.e., about once every 5, 6, 7, 8, or 9 days), most preferably about once every 7 days.
- PEGVISOMANT is administered with a frequency of between about once per day and about once every month, inclusive, preferably between about once every 3 days (i.e., about every 2, 3, or 4 days) and about once every 14 days, inclusive, more preferably about once per week, (i.e., about once every 5, 6, 7, 8, or 9 days), most preferably about once every 7 days.
- said subject is a human who suffers from acromegaly and said somatostatin agonist comprises OCTREOTIDE or LANREOTIDE, wherein said OCTREOTIDE or said LANREOTIDE is administered with a frequency of between about five times per day and about once every 6 months, inclusive, preferably between about three times per day and about once every 3 months, inclusive, more preferably between about once per day and about once per month, inclusive, more preferably about once per month. More preferably when said somatostatin agonist is OCTREOTIDE it is provided as OCTREOTIDE LAR, and when said somatostatin agonist is LANREOTIDE it is provided as LANREOTIDE AUTOGEL.
- said human subject suffers from acromegaly, said GH antagonist comprises PEGVISOMANT, and said somatostatin agonist comprises OCTREOTIDE, wherein said PEGVISOMANT is administered about once per week and said OCTREOTIDE is administered about once per month.
- said human subject suffers from acromegaly, said GH antagonist comprises PEGVISOMANT, and said somatostatin agonist comprises LANREOTIDE, wherein said PEGVISOMANT is administered about once per week and said LANREOTIDE is administered about once per month.
- Figure 1 Normalization of serum IGF-I concentration in 19 acromegalic patients before and after adding once weekly pegvisomant to high-dose monthly somatostatin analogue therapy in a dose finding study with a treatment duration of 42 weeks and dose increments to a maximum of 80 mg of pegvisomant per week.
- the shaded area indicates the age-dependent normal ranges for IGF-I.
- octreotide LAR also known as SANDOSTATIN LAR
- 120 mg of Lanreotide autogel also known as SOMATULINE AUTOGEL
- Starting dose of pegvisomant was 25 mg per week.
- Pegvisomant dosage was adjusted until serum IGF-I concentrations were within the age-adjusted normal range.
- Efficacy was determined at week 42, which was 6 weeks after patients could have reached the maximal allowed dose of 80 mg when necessary. Efficacy parameters were assessed just prior to the next weekly pegvisomant administration. Serum IGF-I concentration were measured by an immunometric assay (Diagnostic Products Corporation; Los Angeles, USA). A Wilcoxon's signed rank test was used for assessing significance of changes from baseline. Statistical significance was accepted at p-values ⁇ 0.05.
- pegvisomant is needed when there is less GH to compete with, e.g. during co-treatment with a somatostatin analogue.
- lower insulin levels in the portal vein, with somatostatin analog therapy will decrease the number of available GH receptors at the cell surface of the hepatocytes (7).
- Somatostatin analogues might also increase pegvisomant levels by unknown mechanisms (4).
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0609355-8A BRPI0609355A2 (en) | 2005-04-13 | 2006-04-13 | use of a growth hormone antagonist and a somatostatin or a somatostatin agonist in the preparation of a composition to attenuate the effects of growth hormone |
JP2008505823A JP2008535882A (en) | 2005-04-13 | 2006-04-13 | Treatment |
CA002604381A CA2604381A1 (en) | 2005-04-13 | 2006-04-13 | Use of growth hormone antagonist and somatostatin agonist |
EP06742584A EP1874355A2 (en) | 2005-04-13 | 2006-04-13 | Method of treatment using gh antagonist and somatostatin agonist |
AU2006233715A AU2006233715A1 (en) | 2005-04-13 | 2006-04-13 | Method of treatment using GH antagonist and somatostatin agonist |
US11/918,460 US20090215676A1 (en) | 2005-04-13 | 2006-04-13 | Method of treatment |
MX2007012814A MX2007012814A (en) | 2005-04-13 | 2006-04-13 | Method of treatment using gh antagonist and somatostatin agonist. |
AU2010257328A AU2010257328A1 (en) | 2005-04-13 | 2010-12-20 | Method of treatment using GH antagonist and somatostatin agonist |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67074005P | 2005-04-13 | 2005-04-13 | |
US60/670,740 | 2005-04-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006108667A2 true WO2006108667A2 (en) | 2006-10-19 |
WO2006108667A3 WO2006108667A3 (en) | 2007-05-03 |
Family
ID=36968804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/003438 WO2006108667A2 (en) | 2005-04-13 | 2006-04-13 | Method of treatment using gh antagonist and somatostatin agonist |
Country Status (10)
Country | Link |
---|---|
US (1) | US20090215676A1 (en) |
EP (1) | EP1874355A2 (en) |
JP (1) | JP2008535882A (en) |
CN (1) | CN101163505A (en) |
AU (2) | AU2006233715A1 (en) |
BR (1) | BRPI0609355A2 (en) |
CA (1) | CA2604381A1 (en) |
MX (1) | MX2007012814A (en) |
RU (1) | RU2397778C2 (en) |
WO (1) | WO2006108667A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016077620A1 (en) * | 2014-11-12 | 2016-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Treatment of hormonal disorders of growth |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103087182B (en) * | 2013-02-06 | 2014-11-05 | 中国科学院过程工程研究所 | N-terminal site-specific modified PEGylated growth hormone antagonist and its preparation method |
AU2014280847B2 (en) * | 2013-06-13 | 2019-07-04 | Antisense Therapeutics Ltd | Combination therapy |
KR102167827B1 (en) * | 2017-12-20 | 2020-10-20 | 주식회사 알테오젠 | Novel Growth Hormone Receptor Antagonists and Fusion Proteins Thereof |
WO2020014307A1 (en) * | 2018-07-11 | 2020-01-16 | Ohio University | Peptide-based inhibitors of growth hormone action and methods of the thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005021023A1 (en) * | 2003-09-02 | 2005-03-10 | Pharmacia & Upjohn Company | Therapeutical conversion |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1568772T3 (en) * | 1995-09-21 | 2010-10-18 | Genentech Inc | Variants of Human Growth Hormone |
-
2006
- 2006-04-13 CN CNA2006800123486A patent/CN101163505A/en active Pending
- 2006-04-13 EP EP06742584A patent/EP1874355A2/en not_active Withdrawn
- 2006-04-13 RU RU2007141935/14A patent/RU2397778C2/en not_active IP Right Cessation
- 2006-04-13 BR BRPI0609355-8A patent/BRPI0609355A2/en not_active IP Right Cessation
- 2006-04-13 JP JP2008505823A patent/JP2008535882A/en active Pending
- 2006-04-13 CA CA002604381A patent/CA2604381A1/en not_active Abandoned
- 2006-04-13 MX MX2007012814A patent/MX2007012814A/en unknown
- 2006-04-13 AU AU2006233715A patent/AU2006233715A1/en not_active Abandoned
- 2006-04-13 WO PCT/EP2006/003438 patent/WO2006108667A2/en active Application Filing
- 2006-04-13 US US11/918,460 patent/US20090215676A1/en not_active Abandoned
-
2010
- 2010-12-20 AU AU2010257328A patent/AU2010257328A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005021023A1 (en) * | 2003-09-02 | 2005-03-10 | Pharmacia & Upjohn Company | Therapeutical conversion |
Non-Patent Citations (3)
Title |
---|
FEENSTRA J ET AL: "Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly" LANCET THE, LANCET LIMITED. LONDON, GB, vol. 365, no. 9471, 7 May 2005 (2005-05-07), pages 1644-1646, XP004882310 ISSN: 0140-6736 * |
JORGENSEN JENS OTTO LUNDE ET AL: "Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist" JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 90, no. 10, October 2005 (2005-10), pages 5627-5631, XP002425118 ISSN: 0021-972X * |
KOPCHICK J J ET AL: "Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly." ENDOCRINE REVIEWS OCT 2002, vol. 23, no. 5, October 2002 (2002-10), pages 623-646, XP002425117 ISSN: 0163-769X cited in the application * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016077620A1 (en) * | 2014-11-12 | 2016-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Treatment of hormonal disorders of growth |
US10350273B2 (en) | 2014-11-12 | 2019-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Treatment of hormonal disorders of growth |
AU2015346277B2 (en) * | 2014-11-12 | 2020-03-26 | Centre Hospitalier Universitaire De Liège | Treatment of hormonal disorders of growth |
AU2020203709B2 (en) * | 2014-11-12 | 2022-09-29 | Centre Hospitalier Universitaire De Liège | Treatment of hormonal disorders of growth |
Also Published As
Publication number | Publication date |
---|---|
RU2397778C2 (en) | 2010-08-27 |
US20090215676A1 (en) | 2009-08-27 |
JP2008535882A (en) | 2008-09-04 |
CA2604381A1 (en) | 2006-10-19 |
BRPI0609355A2 (en) | 2010-03-30 |
EP1874355A2 (en) | 2008-01-09 |
MX2007012814A (en) | 2008-01-22 |
WO2006108667A3 (en) | 2007-05-03 |
AU2010257328A1 (en) | 2011-01-20 |
CN101163505A (en) | 2008-04-16 |
AU2006233715A1 (en) | 2006-10-19 |
RU2007141935A (en) | 2009-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Elisha et al. | Body composition and epicardial fat in type 2 diabetes patients following insulin detemir versus insulin glargine initiation | |
US11510963B1 (en) | Method of treating diseases | |
US20230201302A1 (en) | Oral octreotide administered in combination with other therapeutic agents | |
Burness et al. | Lanreotide Autogel®: A review of its use in the treatment of patients with acromegaly | |
Puig-Domingo et al. | Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study | |
AU2010257328A1 (en) | Method of treatment using GH antagonist and somatostatin agonist | |
KR20150106887A (en) | Fusion of human growth hormone and albumin, formulation and uses thereof | |
KR20090019896A (en) | Combination of somatostatin-analogs with dopamine or growth hormone receptor antagonist | |
Croxtall et al. | Lanreotide Autogel®: A review of its use in the management of acromegaly | |
Paisley et al. | Medical treatment in acromegaly | |
Chanson | Emerging drugs for acromegaly | |
Bronstein | Optimizing acromegaly treatment | |
Frost et al. | Growth hormone/insulin-like growth factor axis in human immunodeficiency virus-associated disease | |
Frara et al. | Medical treatment in acromegaly | |
Nowicka et al. | Pegvisomant therapy in acromegalic patient resistant to other treatment: case report | |
Witek et al. | Cushing’s disease: is pasireotide LAR a breakthrough in adjuvant therapy after unsuccessful surgery? | |
Said et al. | Pancreatic islet cell carcinoma presenting with concurrent Cushing's and Zollinger–Ellison syndromes: case series and literature review | |
Rioperez et al. | Conn's syndrome in a patient with acromegaly | |
Meas et al. | An unusual somatotropin and thyreotropin secreting pituitary adenoma efficiently controlled by Octreotide and Pegvisomant | |
Oyesiku | Management of recurrent growth hormone-secreting adenomas | |
Millner et al. | Treatment update on acromegaly | |
JP2005523915A (en) | Treatment of metabolic syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 561942 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006233715 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2604381 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008505823 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/012814 Country of ref document: MX Ref document number: 200680012348.6 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006742584 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006233715 Country of ref document: AU Date of ref document: 20060413 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006233715 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007141935 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006742584 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11918460 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0609355 Country of ref document: BR Kind code of ref document: A2 |